Form 4 for VRCA Verrica Pharmaceuticals Inc.
Accepted 2025-11-25 00:00:00 ET · period of report 2025-11-25 · accession 0001494695-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-25 | 2025-11-25 | VRCA | Manning Paul B | Dir, 10% | P - Purchase | $4.24 | +1.38M | 3.96M | +53% | +$5.83M |
| DI | 2025-11-25 | 2025-11-25 | VRCA | Manning Paul B | Dir, 10% | P - Purchase | $4.24 | +2.75M | 3.35M | +460% | +$11.66M |
| D | 2025-11-25 | 2025-11-25 | VRCA | Manning Paul B | Dir, 10% | P - Purchase | — | +343.8K | 343.8K | New | — |
| DI | 2025-11-25 | 2025-11-25 | VRCA | Manning Paul B | Dir, 10% | P - Purchase | — | +687.7K | 687.7K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-25 | P | A | 1,375,380 | $4.24 | 3,958,189 | D | — | — | (F1) Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. (F2) The shares are held by Mr. Manning jointly with his spouse. |
| 2 | Common | Common Stock | 2025-11-25 | P | A | 2,750,762 | $4.24 | 3,348,372 | I See footnote | — | — | (F1) Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. (F3) The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB. |
| 3 | Derivative | Series C Warrant (right to buy) | 2025-11-25 | P | A | 343,845 | — | 343,845 | D | $6.32 · — to 2030-11-25 | 343,845 Common Stock | (F8) The reported securities are included within 1,375,380 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. (F2) The shares are held by Mr. Manning jointly with his spouse. (F7) Immediately exercisable. |
| 4 | Derivative | Series C Warrant (right to buy) | 2025-11-25 | P | A | 687,690 | — | 687,690 | I See footnote | $6.32 · — to 2030-11-25 | 687,690 Common Stock | (F9) The reported securities are included within 2,750,762 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 49.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. (F3) The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of the manager of BKB and has shared voting and investment power with respect to the shares held by BKB. (F7) Immediately exercisable. |